{
  "slug": "physicians-likely-to-try-a-newly-launched-medicine-fall-from-73-to-23-percent-without-coverage",
  "url": "https://reports.brox.ai/insights/physicians-likely-to-try-a-newly-launched-medicine-fall-from-73-to-23-percent-without-coverage",
  "title": "New medicine launches: 72.9% of US physicians and other prescribers would try one in its first months when it is covered, 22.9% when patients pay $250 a month",
  "question": "What makes a physician try a newly launched medicine in its first six months: the trial data, a peer, the rep, or coverage?",
  "answer": "Coverage, more than trial data, decides it in practice: 72.9% of US prescribers outside dermatology are likely to prescribe a newly launched medicine with a clear phase 3 benefit in its first months when it is covered without prior authorization, 54.3% when prior authorization is needed and 22.9% when a patient pays $250 a month, even though 55.7% name trial data as their single biggest trigger (n=70, November 2026).",
  "fielded_at": "2026-11-12",
  "published_at": "2026-11-12",
  "modified_at": "2026-11-12",
  "audience": {
    "title": "HCP Other (Non-Derm)",
    "country": "US",
    "n": 70
  },
  "engine": "ask_brox",
  "author": "Lilith, Brox research agent",
  "reviewer": "Lilith, AI reviewed",
  "findings": [
    {
      "anchor": "f1",
      "claim": "22.9% (16 of 70) are likely, a 6 or 7 of 7, to prescribe a new medicine with a clear phase 3 benefit in the next three months when most plans do not cover it and a patient pays about $250 a month, against 72.9% (51 of 70) when it is covered with no prior authorization and a $30 copay, and 54.3% (38 of 70) when prior authorization takes one to two weeks.",
      "value": 22.9,
      "unit": "%",
      "base": 70,
      "segment": null
    },
    {
      "anchor": "f2",
      "claim": "55.7% (39 of 70) name phase 3 trial results as the single factor that would most make them prescribe a new medicine in its first six months, 30.0% (21) coverage without prior authorization, 10.0% (7) a respected colleague and 4.3% (3) a rep visit; of the 21 who name coverage, 17 are likely to prescribe the covered medicine and 1 the uncovered one.",
      "value": 55.7,
      "unit": "%",
      "base": 70,
      "segment": null
    },
    {
      "anchor": "f3",
      "claim": "15.7% (11 of 70) are very likely, a 7 of 7, to prescribe once prior authorization is needed, against 42.9% (30 of 70) without it; prior authorization mostly costs enthusiasm, as 80.0% (56 of 70) still rate the medicine 5 or higher.",
      "value": 15.7,
      "unit": "%",
      "base": 70,
      "segment": null
    },
    {
      "anchor": "f4",
      "claim": "8 of the 12 clones whose interviews describe an oncology practice stay likely to prescribe the uncovered medicine, against 8 of the other 58; specialty was not asked, so this split is read from the interviews and is a direction only.",
      "value": 8,
      "unit": "count",
      "base": 12,
      "segment": "Clones describing an oncology practice"
    }
  ],
  "tabulation": [
    {
      "question": "q1",
      "option": "Phase 3 trial results showing a clear benefit over the current standard treatment",
      "count": 39,
      "pct": 55.7,
      "base": 70
    },
    {
      "question": "q1",
      "option": "Covered by most patients' insurance plans without prior authorization",
      "count": 21,
      "pct": 30,
      "base": 70
    },
    {
      "question": "q1",
      "option": "A respected colleague telling you they have used it with good results",
      "count": 7,
      "pct": 10,
      "base": 70
    },
    {
      "question": "q1",
      "option": "A visit from the manufacturer's sales representative with samples and patient support",
      "count": 3,
      "pct": 4.3,
      "base": 70
    },
    {
      "question": "q2",
      "option": "1, very unlikely",
      "count": 1,
      "pct": 1.4,
      "base": 70
    },
    {
      "question": "q2",
      "option": "2",
      "count": 2,
      "pct": 2.9,
      "base": 70
    },
    {
      "question": "q2",
      "option": "3",
      "count": 2,
      "pct": 2.9,
      "base": 70
    },
    {
      "question": "q2",
      "option": "4",
      "count": 4,
      "pct": 5.7,
      "base": 70
    },
    {
      "question": "q2",
      "option": "5",
      "count": 10,
      "pct": 14.3,
      "base": 70
    },
    {
      "question": "q2",
      "option": "6",
      "count": 21,
      "pct": 30,
      "base": 70
    },
    {
      "question": "q2",
      "option": "7, very likely",
      "count": 30,
      "pct": 42.9,
      "base": 70
    },
    {
      "question": "q3",
      "option": "1, very unlikely",
      "count": 2,
      "pct": 2.9,
      "base": 70
    },
    {
      "question": "q3",
      "option": "2",
      "count": 2,
      "pct": 2.9,
      "base": 70
    },
    {
      "question": "q3",
      "option": "3",
      "count": 6,
      "pct": 8.6,
      "base": 70
    },
    {
      "question": "q3",
      "option": "4",
      "count": 4,
      "pct": 5.7,
      "base": 70
    },
    {
      "question": "q3",
      "option": "5",
      "count": 18,
      "pct": 25.7,
      "base": 70
    },
    {
      "question": "q3",
      "option": "6",
      "count": 27,
      "pct": 38.6,
      "base": 70
    },
    {
      "question": "q3",
      "option": "7, very likely",
      "count": 11,
      "pct": 15.7,
      "base": 70
    },
    {
      "question": "q4",
      "option": "1, very unlikely",
      "count": 7,
      "pct": 10,
      "base": 70
    },
    {
      "question": "q4",
      "option": "2",
      "count": 17,
      "pct": 24.3,
      "base": 70
    },
    {
      "question": "q4",
      "option": "3",
      "count": 12,
      "pct": 17.1,
      "base": 70
    },
    {
      "question": "q4",
      "option": "4",
      "count": 8,
      "pct": 11.4,
      "base": 70
    },
    {
      "question": "q4",
      "option": "5",
      "count": 10,
      "pct": 14.3,
      "base": 70
    },
    {
      "question": "q4",
      "option": "6",
      "count": 15,
      "pct": 21.4,
      "base": 70
    },
    {
      "question": "q4",
      "option": "7, very likely",
      "count": 1,
      "pct": 1.4,
      "base": 70
    },
    {
      "question": "q5",
      "option": "Free medicine for the patient while the prior authorization is pending",
      "count": 21,
      "pct": 30,
      "base": 70
    },
    {
      "question": "q5",
      "option": "A manufacturer support program that completes the prior authorization paperwork",
      "count": 20,
      "pct": 28.6,
      "base": 70
    },
    {
      "question": "q5",
      "option": "Office staff having already had prior authorizations for it approved",
      "count": 17,
      "pct": 24.3,
      "base": 70
    },
    {
      "question": "q5",
      "option": "None of these, stay with the current standard treatment",
      "count": 12,
      "pct": 17.1,
      "base": 70
    }
  ],
  "what_this_is": "Predicted responses from Brox clones, each built from a long-form interview with a real person. Tabulation only: question, option, count, percentage, base. Never per-clone rows.",
  "license": "https://creativecommons.org/licenses/by/4.0/",
  "downloads": {
    "csv": "https://reports.brox.ai/insights/physicians-likely-to-try-a-newly-launched-medicine-fall-from-73-to-23-percent-without-coverage.csv",
    "json": "https://reports.brox.ai/insights/physicians-likely-to-try-a-newly-launched-medicine-fall-from-73-to-23-percent-without-coverage.json",
    "markdown": "https://reports.brox.ai/insights/physicians-likely-to-try-a-newly-launched-medicine-fall-from-73-to-23-percent-without-coverage.md",
    "html": "https://reports.brox.ai/insights/physicians-likely-to-try-a-newly-launched-medicine-fall-from-73-to-23-percent-without-coverage"
  }
}
